We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunoassay Developed to Diagnose Human Fascioliasis

By LabMedica International staff writers
Posted on 18 Jul 2011
An immunoassay has been evaluated for its diagnostic ability to detect human immunoglobulin G (IgG) antibodies against Fasciola hepatica, a common liver fluke. More...


The indirect enzyme-linked immunosorbent assay (ELISA) that detects antibodies against F. hepatica saposin-like protein-2, was compared with another indirect ELISA that detects excretory–secretory products (FhES) from adult F. hepatica.

Scientists at the University of Puerto Rico (San Juan), analyzed the sera of 37 patients infected with F. hepatica, 40 patients with other parasitic infections, and 50 healthy controls. A recombinant F. hepatica saposin-like protein-2 product was prepared and compared with the FhES products obtained from adult flukes collected from cattle's bile ducts obtained from a slaughterhouse.

The sensitivity of both ELISA assays was 100%. However, the FhSAP2-based ELISA had a specificity of 95.6%, while that of the FhES-ELISA was 91.9%. The results indicate that FhSAP2 is more specific than FhES products as target antigen for ELISA-based serodiagnosis of human fascioliasis since the best results for specificity and accuracy were achieved with the recombinant protein. The investigators noted that the mean value for negative controls and for other groups of samples is higher for the FhSAP2-ELISA than for the FhES-ELISA assay, which leads to a higher cut-off value, and that the mean value for the positive control samples in the FhSAP2-ELISA is slightly lower than the mean value obtained for these samples in the FhES-ELISA.

The authors concluded that their results demonstrated that FhSAP2 could be used in the serodiagnosis of chronic human fascioliasis with the additional advantage of being relatively cheap and easy to produce. Studies are in progress to evaluate this FhSAP2-ELISA assay in a large-scale prevalence surveys in endemic areas. It is estimated that worldwide 180 million humans are at risk from this zoonotic disease. Typical early symptoms include fever, abdominal pain, gastrointestinal disturbances and urticaria and hepatomegaly, anemia and jaundice may also be present The article was published in July 2011, in Diagnostic Microbiology and Infectious Disease.

Related Links:
University of Puerto Rico




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.